Expression of special AT-rich sequence-binding protein 1 is an independent prognostic factor in cutaneous T-cell lymphoma

Grzanka,Dariusz; Gagat,Maciej; Izdebska,Magdalena; Marszałek,Andrzej

doi:10.3892/or.2014.3597

Expression of special AT-rich sequence-binding protein 1 is an independent prognostic factor in cutaneous T-cell lymphoma

Authors:
- Dariusz Grzanka
- Maciej Gagat
- Magdalena Izdebska
- Andrzej Marszałek
View Affiliations

Affiliations: Department and Clinic of Dermatology, Sexually Transmitted Diseases and Immunodermatology, Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, 85-092 Bydgoszcz, Poland, Department of Histology and Embryology, Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, 85-092 Bydgoszcz, Poland, Department of Clinical Pathomorphology, Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, 85-092 Bydgoszcz, Poland
Published online on: November 11, 2014 https://doi.org/10.3892/or.2014.3597
Pages: 250-266

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cutaneous T-cell lymphoma (CTCL) is a group of slowly progressive, lymphoproliferative disorders characterized by localization of neoplastic T lymphocytes to the skin. The most common type of CTCL is mycosis fungoides which has a mild clinical course with slow and long progression. The rate of progression is generally slow and takes many years but often remains unpredictable. Special AT-rich sequence-binding protein-1 (SATB1) is a global chromatin organizer which controls gene expression by folding and remodeling chromatin, but which also regulates the level of histone methylation and acetylation, important in differentiation and apoptosis. The aim of the present study was to determine if SATB1 may be considered a prognostic and predictive factor of CTCL. The results showed that moderate and high expression of SATB1 correlate with significantly better prognosis of CTCL patients. Moreover, we showed that downregulation of SATB1 in Jurkat cells caused their resistance to activation-induced cell death. In conclusion, SATB1 expression appears to be a strong candidate as a prognostic factor confirming the inner heterogeneous features of CTCLs.

View Figures

View References

1	Bradford PT, Devesa SS, Anderson WF and Toro JR: Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 113:5064–5073. 2009. View Article : Google Scholar : PubMed/NCBI
2	Criscione VD and Weinstock MA: Incidence of cutaneous T-cell lymphoma in the United States, 1973–2002. Arch Dermatol. 143:854–859. 2007. View Article : Google Scholar : PubMed/NCBI
3	Pham-Ledard A, Prochazkova-Carlotti M, Laharanne E, Vergier B, Jouary T, Beylot-Barry M and Merlio JP: IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 cases. J Invest Dermatol. 130:816–825. 2010. View Article : Google Scholar
4	Zackheim HS: Cutaneous T cell lymphoma: update of treatment. Dermatology. 199:102–105. 1999. View Article : Google Scholar : PubMed/NCBI
5	Marszałek A, Grzanka A, Grzanka D and Placek W: Correct answer to the quiz. Check your diagnosis Mycosis fungoides - case report and short overview of the literature. Pol J Pathol. 61:54–61. 2010.
6	Al Hothali GI: Review of the treatment of mycosis fungoides and Sézary syndrome: a stage-based approach. Int J Health Sci. 7:220–239. 2013.
7	Wang Y, Su M, Zhou LL, Tu P, Zhang X, Jiang X and Zhou Y: Deficiency of SATB1 expression in Sezary cells causes apoptosis resistance by regulating FasL/CD95L transcription. Blood. 117:3826–3835. 2011. View Article : Google Scholar : PubMed/NCBI
8	Zackheim HS: Treatment of mycosis fungoides/Sezary syndrome: the University of California, San Francisco (UCSF) approach. Int J Dermatol. 42:53–56. 2003. View Article : Google Scholar : PubMed/NCBI
9	Costantini P, Jacotot E, Decaudin D and Kroemer G: Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst. 92:1042–1053. 2000. View Article : Google Scholar : PubMed/NCBI
10	Trautinger F, Knobler R, Willemze R, et al: EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer. 42:1014–1030. 2006. View Article : Google Scholar : PubMed/NCBI
11	Grzanka A, Grzanka D, Gagat M, Tadrowski T, Sokołowska-Wojdyło M, Marszałek A and Placek W: Correlation of SATB1 expression with clinical course of cutaneous T-cell lymphomas. Pol J Pathol. 63:101–105. 2012.PubMed/NCBI
12	Dickinson LA, Joh T, Kohwi Y and Kohwi-Shigematsu T: A tissue-specific MAR/SAR DNA-binding protein with unusual binding site recognition. Cell. 70:631–645. 1992. View Article : Google Scholar : PubMed/NCBI
13	Galande S, Purbey PK, Notani D and Kumar PP: The third dimension of gene regulation: organization of dynamic chromatin loopscape by SATB1. Curr Opin Genet Dev. 17:408–414. 2007. View Article : Google Scholar : PubMed/NCBI
14	Purbey PK, Singh S, Notani D, Kumar PP, Limaye AS and Galande S: Acetylation-dependent interaction of SATB1 and CtBP1 mediates transcriptional repression by SATB1. Mol Cell Biol. 29:1321–1337. 2009. View Article : Google Scholar :
15	Liu J, Barnett A, Neufeld EJ and Dudley JP: Homeoproteins CDP and SATB1 interact: potential for tissue-specific regulation. Mol Cell Biol. 19:4918–4926. 1999.PubMed/NCBI
16	Alvarez JD, Yasui DH, Niida H, Joh T, Loh DY and Kohwi-Shigematsu T: The MAR-binding protein SATB1 orchestrates temporal and spatial expression of multiple genes during T-cell development. Genes Dev. 14:521–535. 2000.PubMed/NCBI
17	Meng W-J, Yan H, Zhou B, et al: Correlation of SATB1 overexpression with the progression of human rectal cancer. Int J Colorectal Dis. 27:143–150. 2012. View Article : Google Scholar
18	Han B, Luan L, Xu Z and Wu B: Expression and biological roles of SATB1 in human bladder cancer. Tumour Biol. 34:2943–2949. 2013. View Article : Google Scholar : PubMed/NCBI
19	Mao L, Yang C, Wang J, Li W, Wen R, Chen J and Zheng J: SATB1 is overexpressed in metastatic prostate cancer and promotes prostate cancer cell growth and invasion. J Transl Med. 11:1112013. View Article : Google Scholar : PubMed/NCBI
20	Shen Z, Zeng Y, Guo J, et al: Over-expression of the special AT rich sequence binding protein 1 (SATB1) promotes the progression of nasopharyngeal carcinoma: association with EBV LMP-1 expression. J Transl Med. 11:2172013. View Article : Google Scholar : PubMed/NCBI
21	Ordinario E, Han H-J, Furuta S, et al: ATM suppresses SATB1-induced malignant progression in breast epithelial cells. PloS One. 7:e517862012. View Article : Google Scholar : PubMed/NCBI
22	Wang Q, Qian J, Wang F and Ma Z: Cellular prion protein accelerates colorectal cancer metastasis via the Fyn-SP1-SATB1 axis. Oncol Rep. 28:2029–2034. 2012.PubMed/NCBI
23	Fang XF, Hou ZB, Dai XZ, et al: Special AT-rich sequence-binding protein 1 promotes cell growth and metastasis in colorectal cancer. World J Gastroenterol. 19:2331–2339. 2013. View Article : Google Scholar : PubMed/NCBI
24	Kobierzycki C, Wojnar A and Dziegiel P: Expression of SATB1 protein in the ductal breast carcinoma tissue microarrays - preliminary study. Folia Histochem Cytobiol. 51:333–338. 2013. View Article : Google Scholar
25	Grzanka D, Gagat M and Izdebska M: Involvement of the SATB1/F-actin complex in chromatin reorganization during active cell death. Int J Mol Med. 33:1441–1450. 2014.PubMed/NCBI
26	Edelson RL: Cutaneous T cell lymphoma: mycosis fungoides, Sézary syndrome, and other variants. J Am Acad Dermatol. 2:89–106. 1980. View Article : Google Scholar : PubMed/NCBI
27	Abel EA: Clinical features of cutaneous T-cell lymphoma. Dermatol Clin. 3:647–664. 1985.PubMed/NCBI
28	Willemze R, Kerl H, Sterry W, et al: EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 90:354–371. 1997.PubMed/NCBI
29	Willemze R, Jaffe ES, Burg G, et al: WHO-EORTC classification for cutaneous lymphomas. Blood. 105:3768–3785. 2005. View Article : Google Scholar : PubMed/NCBI
30	Sausville EA, Eddy JL, Makuch RW, et al: Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups. Ann Intern Med. 109:372–382. 1988. View Article : Google Scholar : PubMed/NCBI
31	Kim YH, Chow S, Varghese A and Hoppe RT: Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. Arch Dermatol. 135:26–32. 1999. View Article : Google Scholar : PubMed/NCBI
32	Weinstock MA and Reynes JF: The changing survival of patients with mycosis fungoides: a population-based assessment of trends in the United States. Cancer. 85:208–212. 1999. View Article : Google Scholar : PubMed/NCBI
33	van Doorn R, van Haselen CW, van Voorst Vader PC, et al: Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol. 136:504–510. 2000. View Article : Google Scholar : PubMed/NCBI
34	Kim YH, Liu HL, Mraz-Gernhard S, Varghese A and Hoppe RT: Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 139:857–866. 2003. View Article : Google Scholar : PubMed/NCBI
35	Agar NS, Wedgeworth E, Crichton S, et al: Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 28:4730–4739. 2010. View Article : Google Scholar : PubMed/NCBI
36	Hess Schmid M, Dummer R, Kempf W, Hilty N and Burg G: Mycosis fungoides with mucinosis follicularis in childhood. Dermatology. 198:284–287. 1999. View Article : Google Scholar : PubMed/NCBI
37	Talpur R, Singh L, Daulat S, et al: Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin Cancer Res. 18:5051–5060. 2012. View Article : Google Scholar : PubMed/NCBI
38	Vicente A, Martí RM, Martín E, Estrach T, Herrero C and Mascaró JM: Mycosis fungoides with oral involvement. Int J Dermatol. 30:864–866. 1991. View Article : Google Scholar : PubMed/NCBI
39	Vonderheid EC, Diamond LW, van Vloten WA, et al: Lymph node classification systems in cutaneous T-cell lymphoma. Evidence for the utility of the Working Formulation of Non-Hodgkin’s Lymphomas for Clinical Usage. Cancer. 73:207–218. 1994. View Article : Google Scholar : PubMed/NCBI
40	Bernengo MG, Quaglino P, Novelli M, et al: Prognostic factors in Sézary syndrome: a multivariate analysis of clinical, haematological and immunological features. Ann Oncol. 9:857–863. 1998. View Article : Google Scholar : PubMed/NCBI
41	Diamandidou E, Colome M, Fayad L, Duvic M and Kurzrock R: Prognostic factor analysis in mycosis fungoides/Sézary syndrome. J Am Acad Dermatol. 40:914–924. 1999. View Article : Google Scholar : PubMed/NCBI
42	Fraser-Andrews EA, Woolford AJ, Russell-Jones R, Seed PT and Whittaker SJ: Detection of a peripheral blood T cell clone is an independent prognostic marker in mycosis fungoides. J Invest Dermatol. 114:117–121. 2000. View Article : Google Scholar : PubMed/NCBI
43	Wasik MA, Vonderheid EC, Bigler RD, Marti R, Lessin SR, Polansky M and Kadin ME: Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications. Arch Dermatol. 132:42–47. 1996. View Article : Google Scholar : PubMed/NCBI
44	Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M and Kurzrock R: Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood. 92:1150–1159. 1998.PubMed/NCBI
45	Vergier B, de Muret A, Beylot-Barry M, et al: Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneous Lymphomas. Blood. 95:2212–2218. 2000.PubMed/NCBI
46	Vidulich KA, Talpur R, Bassett RL and Duvic M: Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. Int J Dermatol. 48:243–252. 2009. View Article : Google Scholar : PubMed/NCBI
47	Olsen E, Vonderheid E, Pimpinelli N, et al: Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 110:1713–1722. 2007. View Article : Google Scholar : PubMed/NCBI
48	Scarisbrick JJ, Kim YH, Whittaker SJ, Wood GS, Vermeer MH, Prince HM and Quaglino P: Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now? Br J Dermatol. 170:1226–1236. 2014. View Article : Google Scholar : PubMed/NCBI
49	Martí RM, Estrach T, Reverter JC and Mascaró JM: Prognostic clinicopathologic factors in cutaneous T-cell lymphoma. Arch Dermatol. 127:1511–1516. 1991. View Article : Google Scholar : PubMed/NCBI
50	Han HJ, Russo J, Kohwi Y and Kohwi-Shigematsu T: SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature. 452:187–193. 2008. View Article : Google Scholar : PubMed/NCBI
51	Pavan Kumar P, Purbey PK, Sinha CK, Notani D, Limaye A, Jayani RS and Galande S: Phosphorylation of SATB1, a global gene regulator, acts as a molecular switch regulating its transcriptional activity in vivo. Mol Cell. 22:231–243. 2006. View Article : Google Scholar : PubMed/NCBI
52	Yasui D, Miyano M, Cai S, Varga-Weisz P and Kohwi-Shigematsu T: SATB1 targets chromatin remodelling to regulate genes over long distances. Nature. 419:641–645. 2002. View Article : Google Scholar : PubMed/NCBI
53	Cai S, Han HJ and Kohwi-Shigematsu T: Tissue-specific nuclear architecture and gene expression regulated by SATB1. Nat Genet. 34:42–51. 2003. View Article : Google Scholar : PubMed/NCBI
54	Notani D, Limaye AS, Kumar PP and Galande S: Phosphorylation-dependent regulation of SATB1, the higher-order chromatin organizer and global gene regulator. Methods Mol Biol. 647:317–335. 2010. View Article : Google Scholar : PubMed/NCBI
55	Satoh Y, Yokota T, Sudo T, et al: The Satb1 protein directs hematopoietic stem cell differentiation toward lymphoid lineages. Immunity. 38:1105–1115. 2013. View Article : Google Scholar : PubMed/NCBI
56	Will B, Vogler TO, Bartholdy B, et al: Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment. Nat Immunol. 14:437–445. 2013. View Article : Google Scholar : PubMed/NCBI
57	Agrelo R, Souabni A, Novatchkova M, et al: SATB1 defines the developmental context for gene silencing by Xist in lymphoma and embryonic cells. Dev Cell. 16:507–516. 2009. View Article : Google Scholar : PubMed/NCBI
58	Zhou LY, Liu F, Tong J, Chen QQ and Zhang FW: Expression of special AT-rich sequence-binding protein mRNA and its clinicopathological significance in non-small cell lung cancer. Nan Fang Yi Ke Da Xue Xue Bao. 29:534–537. 2009.(In Chinese). PubMed/NCBI
59	Li QQ, Chen ZQ, Xu JD, Cao X-X, Chen Q, Liu XP and Xu ZD: Overexpression and involvement of special AT-rich sequence binding protein 1 in multidrug resistance in human breast carcinoma cells. Cancer Sci. 101:80–86. 2010. View Article : Google Scholar
60	Lu X, Cheng C, Zhu S, et al: SATB1 is an independent prognostic marker for gastric cancer in a Chinese population. Oncol Rep. 24:981–987. 2010.PubMed/NCBI
61	Zhao XD, Ji W, Zhang W, He LX, Yang J, Liang HJ and Wang LL: Overexpression of SATB1 in laryngeal squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec. 72:1–5. 2010. View Article : Google Scholar : PubMed/NCBI
62	Chen H, Takahara M, Oba J, et al: Clinicopathologic and prognostic significance of SATB1 in cutaneous malignant melanoma. J Dermatol Sci. 64:39–44. 2011. View Article : Google Scholar : PubMed/NCBI
63	Zhang L, Cheng F, He R, Chen H, Liu Y and Sun J: Inhibition of SATB1 by shRNA suppresses the proliferation of cutaneous malignant melanoma. Cancer Biother Radiopharm. 29:77–82. 2014. View Article : Google Scholar : PubMed/NCBI
64	Bayer AL, Chirinos J, Cabello C, Yang J, Matsutani T, Malek TR and Levy RB: Expansion of a restricted residual host T reg-cell repertoire is dependent on IL-2 following experimental auto-logous hematopoietic stem transplantation. Eur J Immunol. 41:3467–3478. 2011. View Article : Google Scholar : PubMed/NCBI
65	Berger CL, Tigelaar R, Cohen J, Mariwalla K, Trinh J, Wang N and Edelson RL: Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood. 105:1640–1647. 2005. View Article : Google Scholar
66	Capriotti E, Vonderheid EC, Thoburn CJ, Wasik MA, Bahler DW and Hess AD: Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma. Leuk Lymphoma. 49:1190–1201. 2008. View Article : Google Scholar : PubMed/NCBI
67	Heid JB, Schmidt A, Oberle N, Goerdt S, Krammer PH, Suri-Payer E and Klemke CD: FOXP3⁺CD25⁻ tumor cells with regulatory function in Sézary syndrome. J Invest Dermatol. 129:2875–2885. 2009. View Article : Google Scholar : PubMed/NCBI